Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA)

Merck (MRK) said Wednesday it will acquire clinical-stage biotech Terns Pharmaceuticals (TERN) in an all-cash transaction valued at about $6.7 billion, further expanding its oncology pipeline.
Against this backdrop, below is a list of the top 10 U.S.-listed pharmaceutical stocks ranked